Long-term effects of non-retrieved inferior vena cava filters on recurrences of venous thromboembolism in cancer and non-cancer patients: From the COMMAND VTE registry

Published:September 10, 2020DOI:



      There is a paucity of data comparing the long-term outcomes after inferior vena cava (IVC) filters placement for patients with acute venous thromboembolism (VTE) between those with and without active cancer.


      In the COMMAND VTE Registry, we evaluated the effects of IVC filter use on the long-term clinical outcomes stratified by the presence and absence of active cancer.


      Among 2,626 patients with acute symptomatic VTE, there were 604 patients with active cancer, and 2022 patients without active cancer. IVC filters were placed and not retrieved in 455 patients (17%) in the entire cohort, in 150 patients (24.8%) in the active cancer stratum, and in 305 patients (15.1%) in the non-cancer stratum. In the entire cohort, non-retrieved IVC filter placement was not associated with a lower adjusted risk for PE recurrence (HR 0.59, 95% CI 0.30–1.15, P = 0.122), but with an increased adjusted risk for DVT recurrence (HR 2.27, 95% CI 1.43–3.60, P<0.001). In the non-cancer stratum, the non-retrieved IVC filter placement was associated with a decreased risk for PE (HR 0.29, 95% CI 0.09–0.93, P = 0.037), but not with an increased risk for DVT (HR 1.73, 95% CI 0.89–3.38, P = 0.108), while in the active cancer stratum, it was associated with an increased risk for DVT (HR 2.47, 95% CI 1.24–4.91, P = 0.010), but not with a decreased risk for PE (HR 0.82, 95% CI 0.34-–1.96, P = 0.650).


      There were some differences in the risk-benefit balance between VTE patients with and without active cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mismetti P
        • Laporte S.
        Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism a randomized clinical trial.
        JAMA. 2015; 313: 1627-1635
        • Joint Working Group JCS
        Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS2009).
        Circ J. 2011; 75: 1258-1281
        • Konstantinides SV
        • Torbicki A
        • Agnelli G
        • Danchin N
        • Fitzmaurice D
        • Galiè N
        • et al.
        ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur Heart J. 2014; 35: 3033-3069
        • Timp JF
        • Braekkan SK.
        Epidemiology of cancer-associated venous thrombosis.
        Blood. 2013; 122: 1712-1723
        • Blom JW
        • Doggen CJ
        Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
        JAMA. 2005; 293: 715-722
        • Hutten BA
        • Prins MH
        • Gent M
        • Ginsberg J
        • Tijssen JG
        • Büller HR
        Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
        J Clin Oncol. 2000; 18: 3078-3083
        • Weinberg I
        • Kaufman J
        Inferior vena cava filters.
        JACC Cardiovasc Interv. 2013; 6: 539-547
        • Yamashita Y
        • Morimoto T
        • Amano H
        • Takase T
        • Hiramori S
        • Kim K
        • et al.
        Anticoagulation Therapy for Venous Thromboembolism in the Real World- From the COMMAND VTE Registry.
        Circ J. 2018; 82: 1262-1270
        • Yamashita Y
        • Morimoto T
        • Amano H
        • Takase T
        • Hiramori S
        • Kim K
        • et al.
        Influence of baseline anemia on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry.
        J Thromb Thrombolysis. 2019; 47: 444-453
        • Jaff MR
        • McMurtry MS
        • Archer SL
        • Cushman M
        • Goldenberg N
        • Goldhaber SZ
        • et al.
        Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the american heart association.
        Circulation. 2011; 123: 1788-1830
        • Kearon C
        • Akl EA
        • Ornelas J
        • Blaivas A
        • Jimenez D
        • Bounameaux H
        • et al.
        Antithrombotic therapy for VTE disease: Chest guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Athanasoulis CA
        • Kaufman JA
        • Halpern EF
        • Waltman AC
        • Geller SC
        • Fan C
        Inferior vena caval filters: review of a 26-year single-center experience.
        Radiology. 2000; 216: 54-66
        • The PREPIC Study Group
        Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism.
        Circulation. 2005; 112: 416-422
        • Prandoni P
        • Lensing AW
        • Büller HR
        • Cogo A
        • Prins MH
        • Cattelan AM
        • et al.
        Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.
        N Engl J Med. 1992; 327: 1128-1133
        • Prandoni P
        • Lensing AW
        • Piccioli A
        • Bernardi E
        • Simioni P
        • Girolami B
        • et al.
        Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
        Blood. 2002; 100: 3484-3488
        • Imberti D
        • Agnelli G
        • Ageno W
        • Moia M
        • Palareti G
        • Pistelli R
        • et al.
        Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.
        Haematologica. 2008; 93: 273-278
        • Kaufman JA
        • Kinney TB
        • Streiff MB
        • Sing RF
        • Proctor MC
        • Becker D
        • et al.
        Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference.
        J Vasc Interv Radiol. 2006; 17: 449-459
        • Kearon C
        • Akl EA
        • Comerota AJ
        • Prandoni P
        • Bounameaux H
        • Goldhaber SZ
        • et al.
        Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis.
        9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 141. Chest, 2012: e419S-e496S
        • Brunson A
        • Ho G
        • White R
        • Wun T
        Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study.
        Thromb Res. 2017; 153: 57-64
        • Abtahin F
        • Hawkins BM
        Inferior vena cava filter usage, complications, and retrieval rate in cancer patients.
        AM J Med. 2014; 127: 1111-1117
        • Mission JF
        • Kerlan Jr, RK
        • Tan JH
        • Fang MC
        Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients.
        J Gen Intern Med. 2010; 25: 321-325
        • Nishimoto Y
        • Yamashita Y
        • Morimoto T
        • Saga S
        • Amano H
        • Takase T
        • et al.
        Thrombolysis with tissue plasminogen activator in patients with acute pulmonary embolisms in the real world: from the COMMAND VTE registry.
        J Thromb Thrombolysis. 2019; 48: 587-595